Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Equity Income (2018 - 2022)

Historic Equity Income for Theravance Biopharma (TBPH) over the last 5 years, with Q2 2022 value amounting to $28.1 million.

  • Theravance Biopharma's Equity Income rose 2828.15% to $28.1 million in Q2 2022 from the same period last year, while for Jun 2022 it was $118.8 million, marking a year-over-year increase of 6489.76%. This contributed to the annual value of $104.0 million for FY2021, which is 5194.34% up from last year.
  • Per Theravance Biopharma's latest filing, its Equity Income stood at $28.1 million for Q2 2022, which was up 2828.15% from $25.1 million recorded in Q1 2022.
  • Theravance Biopharma's Equity Income's 5-year high stood at $35.3 million during Q4 2021, with a 5-year trough of $686000.0 in Q1 2018.
  • Over the past 5 years, Theravance Biopharma's median Equity Income value was $13.5 million (recorded in 2020), while the average stood at $15.0 million.
  • As far as peak fluctuations go, Theravance Biopharma's Equity Income surged by 80801.75% in 2019, and later surged by 254.9% in 2021.
  • Quarter analysis of 5 years shows Theravance Biopharma's Equity Income stood at $5.4 million in 2018, then soared by 119.47% to $11.9 million in 2019, then skyrocketed by 69.05% to $20.1 million in 2020, then soared by 75.31% to $35.3 million in 2021, then fell by 20.33% to $28.1 million in 2022.
  • Its Equity Income was $28.1 million in Q2 2022, compared to $25.1 million in Q1 2022 and $35.3 million in Q4 2021.